Lung Cancer Therapeutics Market Size, Share and Industry Analysis By Therapy (Targeted, Therapy, Immunotherapy, Chemotherapy), By Cancer Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast 2026-2034

Last Updated: March 16, 2026 | Format: PDF | Report ID: FBI100473

To get information on various segments, share your queries with us

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Forecast Period	2026-2034
Historical Period	2021-2024
Unit	Value (USD Billion)
CAGR	13.47
Segmentation	By Therapy Targeted Therapy Bevacizumab Dabrafenib/Trametinib Erlotinib Hydrochloride Osimertinib Others Immunotherapy Durvalumab Nivolumab Atezolizumab Pembrolizumab Chemotherapy
	By Cancer Type Non-small cell lung cancer (NSCLC) Small cell lung cancer (SCLC)
	By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
	By Geography North America (U.S., and Canada) Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe) Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and the Rest of Latin America) Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)